AMES, Iowa, March 21 /PRNewswire-FirstCall/ -- BioForce Nanosciences
Holdings, Inc. ("BioForce"), (OTC Bulletin Board: BFNH), today announced that
it has closed a $6 million Private Placement of restricted common shares
@$1.50/share. The company's shares trade under the symbol BFNH.
Dr. Eric Henderson, BioForce founder and CEO and an early developer of
nanotechnology tools, said, "With this financing, and the recent addition of
key senior management, BioForce is well positioned to take full advantage of
the commercial opportunities that our NanoArrayer(TM) System provides. This
funding will also facilitate continued development of the company's pipeline
BioForce's core technology, the NanoArrayer(TM) System, is a proprietary
instrumentation and software tool that is poised to impact multiple areas in
the life sciences. The NanoArrayer(TM) is a new and enabling platform for
addressing previously intractable research problems, thereby enhancing the
opportunity for scientific breakthroughs.
The company is also commercializing a patented diagnostic device called
the ViriChip(TM) System, which is used for detection and identification of
multiple viruses and other pathogens simultaneously on a single chip. The
ViriChip(TM) is a consumable product that creates a recurring revenue
About BioForce Nanosciences Holdings, Inc.
BioForce creates products that enable future advances in nanotechnology
across a broad spectrum of industries. The company has developed, patented and
initiated commercialization of a unique instrument called the NanoArrayer(TM).
The NanoArrayer(TM) is a tabletop device with the ability to print and pattern
thousands of molecular domains on a chip in an extremely miniaturized format.
Another emphasis of the company is the patented ViriChip(TM) System for the
direct, non-destructive and simultaneous detection and identification of
multiple viruses. BioForce is synergistically expanding its technology
foundation with a pipeline of additional tools and devices through both
internal and external growth. The company's founder and CEO, Dr. Eric
Henderson, is a pioneer in the application of nanotechnology to life sciences
research and development.
This news release may contain certain forward-looking statements within
the meaning of applicable securities laws. Forward-looking statements are
based on current expectations and the current economic environment. Readers
are cautioned not to put undue reliance on such forward-looking statements.
Unknown risks and uncertainties, including those described in the company's
most recent filings with the Securities and Exchange Commission, may cause
actual results to differ materially from those contained in forward-looking
statements. The forward-looking statements are made only as of the date of
this news release and the company assumes no duty to publicly update these
statements to reflect subsequent events or circumstances.
SOURCE BioForce Nanosciences Holdings, Inc.